September 1, 2024Diseases of the EsophagusOpen Access

Influence of Neoadjuvant Immunotherapy-Chemotherapy on Perioperative Outcomes in Locally Advanced Esophageal Adenocarcinoma

View Full Paper

Ask AI

Bookmark

Authors

YNYehonatan NevoMcGill University Health Centre JTJames TankelMontreal General Hospital HZHenry ZaoMcGill University Health Centre

Discussion

Member takes

Implication

Non-randomized phase II trial reveals similar perioperative complication rates with neoadjuvant immunotherapy added to chemotherapy in esophageal adenocarcinoma, suggesting surgical safety.

Key Points

Adding avelumab immunotherapy to neoadjuvant chemotherapy yields comparable perioperative complication rates, demonstrating preserved surgical safety in esophageal adenocarcinoma.
Major complication rates reached 26% with immunotherapy compared to 20% with neoadjuvant chemotherapy alone, showing no statistically significant difference after esophagectomy.
Single center non-randomized phase II trial evaluated 49 patients receiving avelumab and chemotherapy against 50 matched controls undergoing esophagectomy for advanced cancer.

Cite This Study

Nevo et al. (2024) studied this question.

synapsesocial.com/papers/68e59e9db6db643587539148 https://doi.org/10.1093/dote/doae057.368

View Full Paper

Ask AI

Bookmark

Implication

Non-randomized phase II trial reveals similar perioperative complication rates with neoadjuvant immunotherapy added to chemotherapy in esophageal adenocarcinoma, suggesting surgical safety.

Influence of Neoadjuvant Immunotherapy-Chemotherapy on Perioperative Outcomes in Locally Advanced Esophageal Adenocarcinoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Influence of Neoadjuvant Immunotherapy-Chemotherapy on Perioperative Outcomes in Locally Advanced Esophageal Adenocarcinoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider